Free Trial
NASDAQ:MESO

Mesoblast (MESO) Stock Price, News & Analysis

Mesoblast logo
$10.79 -0.07 (-0.64%)
Closing price 07/3/2025 03:26 PM Eastern
Extended Trading
$10.79 0.00 (0.00%)
As of 07/3/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Mesoblast Stock (NASDAQ:MESO)

Key Stats

Today's Range
$10.56
$10.82
50-Day Range
$10.16
$12.71
52-Week Range
$5.78
$22.00
Volume
208,906 shs
Average Volume
277,456 shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Mesoblast Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

MESO MarketRank™: 

Mesoblast scored higher than 47% of companies evaluated by MarketBeat, and ranked 564th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mesoblast has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mesoblast has received no research coverage in the past 90 days.

  • Read more about Mesoblast's stock forecast and price target.
  • Earnings Growth

    Earnings for Mesoblast are expected to grow in the coming year, from ($0.70) to ($0.32) per share.

  • Price to Book Value per Share Ratio

    Mesoblast has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Mesoblast's valuation and earnings.
  • Percentage of Shares Shorted

    2.59% of the float of Mesoblast has been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mesoblast has recently increased by 3.07%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Mesoblast does not currently pay a dividend.

  • Dividend Growth

    Mesoblast does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.59% of the float of Mesoblast has been sold short.
  • Short Interest Ratio / Days to Cover

    Mesoblast has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Mesoblast has recently increased by 3.07%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Mesoblast has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Mesoblast this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mesoblast insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.43% of the stock of Mesoblast is held by institutions.

  • Read more about Mesoblast's insider trading history.
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Stock News Headlines

Trump's ticking time bomb
A looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House document might be the real trigger. One market expert who predicted major collapses in 2008 is now warning of a second, far more explosive directive tied to America’s most vital resource. If he’s right, it could set off a financial shock unlike anything we’ve seen in decades.
Mesoblast Limited (MSB.AX)
See More Headlines

MESO Stock Analysis - Frequently Asked Questions

Mesoblast's stock was trading at $19.80 at the start of the year. Since then, MESO stock has decreased by 45.5% and is now trading at $10.79.

Mesoblast Limited (NASDAQ:MESO) issued its earnings results on Wednesday, August, 30th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.06. The business earned $2.14 million during the quarter, compared to the consensus estimate of $2 million.
Read the conference call transcript
.

Shares of Mesoblast reverse split on the morning of Friday, January 5th 2024.The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split.

Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Corbus Pharmaceuticals (CRBP).

Company Calendar

Last Earnings
8/30/2023
Today
7/06/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$24.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+66.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.67 million
Price / Cash Flow
N/A
Book Value
$4.21 per share
Price / Book
2.56

Miscellaneous

Free Float
103,756,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
2.39

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:MESO) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners